The structure of the drug therapy prescription to cardiac patients during the primary care: the lessons of the OZIRKA study

Authors

  • O.O. Torbas State Institution “National Scientific Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine, Ukraine
  • S.M. Kushnir State Institution “National Scientific Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine, Ukraine
  • O.L. Rekovets State Institution “National Scientific Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine, Ukraine
  • Yu.M. Sirenko State Institution “National Scientific Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine, Ukraine

DOI:

https://doi.org/10.22141/2224-1485.14.4.2021.240253

Keywords:

lipid metabolism disorders, hypercholesterolemia, treatment, rosuvastatin

Abstract

The structure of prescriptions of cardiac drugs by the primary care physicians has remained unknown for a long time. We decided to use the data of the OZIRKA study, which aimed to investigate the effect of Ozalex (rosuvastatin) on lipid and cholesterol levels in patients with lipid metabolism disorders and hypercholesterolemia, and to assess the structure of prescriptions in real clinical practice, as well as the effectiveness of cardiovascular risk factors monitoring. We sincerely hope that the data we have obtained will optimize the treatment plan for primary care patients, improve their prognosis and survival, and provide the practitioner with evidence of the safety and efficacy of rosuvastatin that can be transferred to routine clinical practice.

References

Vasudevan A.R., Hamirani Y.S., Jones P.H. Safety of statins: effects on muscle and the liver. Cleve Clin. J. Med. 2005 Nov. 72(11). 990-3, 996-1001.

Tobert J.A., Newman C.B. Statin tolerability: In defence of placebo-controlled trials. Eur. J. Prev. Cardiol. 2016. 23(8). 891-896.

Cai T., Abel L., Langford O., Monaghan G., Aronson J.K., Stevens R.J. et al. Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses. BMJ. 2021. 374. n1537.

Doumas M., Imprialos K., Dimakopoulou A., Stavropoulos K., Binas A., Athyros V.G. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. Curr. Pharm. Des. 2018. 24(38). 4587-4592.

Katsiki N., Mikhailidis D.P., Mantzoros C.S. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016 Aug. 65(8). 1109-23.

Knuuti J. et al. ESC Scientific Document Group, 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal. 2020. Vol. 41. Issue 3. P. 407-477.

Zhang X.J., Qin J.J., Cheng X. et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell. Metab. 2020 Aug 4. 32(2). 176-187.e4.

Сіренко Ю.М., Торбас О.О., Кушнір С.М. Субаналіз дослідження ОЗІРКА: ефективність препарату Озалекс (розувастатин) у пацієнтів із цукровим діабетом. Артеріальна гіпертензія. 2021. Т. 14 (№ 2). С. 30-38.

Balkrishnan R., Phatak H., Gleim G. et al. Assessment of the use of angiotensin receptor blockers in major European markets among paediatric population for treating essential hypertension. J. Hum. Hypertens. 2009. 23. 420-425.

Bryan W. et al. ESC Scientific Document Group / 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur. Heart J. 2018. Vol. 39. Issue 33. P. 3021-3104.

Cosentino F. et al. ESC Scientific Document Group / 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2020. Vol. 41. Issue 2. P. 255-323.

Наказ Міністерства охорони здоров’я від 24 травня 2012 року № 384 «Про затвердження та впровадження медико-технологічних документів зі стандартизації медичної допомоги при артеріальній гіпертензії».

Toutouzas K., Drakopoulou M., Markou V., Karabelas I., Vaina S., Vavuranakis M., Tsiamis E., Tsioufis C., Androulakis A., Stefanadis C. Correlation of systemic inflammation with local inflammatory activity in non-culprit lesions: beneficial effect of statins. Int. J. Cardiol. 2007 Jul 31. 119(3). 368-73.

Heymann E.P., Kassimatis T.I., Goldsmith D.J. Dyslipidemia, statins, and CKD patients outcomes — review of the evidence in the post-sharp era. J. Nephrol. 2012 Jul-Aug. 25(4). 460-72.

Hong K.S., Lee J.S. Statins in Acute Ischemic Stroke: A Systematic Review. J. Stroke. 2015 Sep. 17(3). 282-301.

Published

2021-10-08

Issue

Section

Clinical Researches